- Home
- YSG vs IMTX Comparison
YSG vs IMTX Comparison
Compare YSG & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- IMTX
- Stock Information
- Founded
- YSG 2016
- IMTX N/A
- Country
- YSG China
- IMTX Germany
- Employees
- YSG N/A
- IMTX N/A
- Industry
- YSG Package Goods/Cosmetics
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YSG Consumer Discretionary
- IMTX Health Care
- Exchange
- YSG Nasdaq
- IMTX Nasdaq
- Market Cap
- YSG 889.0M
- IMTX 865.5M
- IPO Year
- YSG 2020
- IMTX N/A
- Fundamental
- Price
- YSG $6.50
- IMTX $9.04
- Analyst Decision
- YSG
- IMTX Strong Buy
- Analyst Count
- YSG 0
- IMTX 4
- Target Price
- YSG N/A
- IMTX $13.67
- AVG Volume (30 Days)
- YSG 237.8K
- IMTX 664.5K
- Earning Date
- YSG 11-20-2025
- IMTX 11-14-2025
- Dividend Yield
- YSG N/A
- IMTX N/A
- EPS Growth
- YSG N/A
- IMTX N/A
- EPS
- YSG N/A
- IMTX N/A
- Revenue
- YSG $522,879,337.00
- IMTX $152,823,253.00
- Revenue This Year
- YSG $24.18
- IMTX N/A
- Revenue Next Year
- YSG $14.76
- IMTX $13.52
- P/E Ratio
- YSG N/A
- IMTX N/A
- Revenue Growth
- YSG 11.53
- IMTX 83.61
- 52 Week Low
- YSG $3.01
- IMTX $3.30
- 52 Week High
- YSG $11.57
- IMTX $11.25
- Technical
- Relative Strength Index (RSI)
- YSG 33.12
- IMTX 44.41
- Support Level
- YSG $6.33
- IMTX $9.99
- Resistance Level
- YSG $6.98
- IMTX $10.70
- Average True Range (ATR)
- YSG 0.41
- IMTX 0.50
- MACD
- YSG -0.07
- IMTX -0.29
- Stochastic Oscillator
- YSG 6.21
- IMTX 13.89
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.